Brentuximab tops chemo in HL, doc says



vials_syringe_240.jpg
Vials of a drug

Brentuximab vendotin—not conventional chemotherapy—is the second-line regimen of choice for recurrent Hodgkin lymphoma (HL) patients prior to stem cell transplant, according to a speaker at the Lymphoma & Myeloma 2014 congress. Catherine Diefenbach, MD, of New York University’s Langone Medical Center in New York, argued that conventional chemotherapy, the existing paradigm... [Read Article]

Speaker advocates chemo-based salvage in HL



young_adult_pt_receiving_chemo_Credit_Rhoda_Baer_230.jpg
Patient receiving chemotherapy
Credit: Rhoda Baer

Physicians should use chemotherapy-based approaches—not brentuximab vedotin—as second-line therapy for recurrent Hodgkin lymphoma (HL) prior to transplant, according to a speaker at the Lymphoma & Myeloma 2014 congress. Nina Wagner-Johnston, MD, of Washington University in St Louis, Missouri, provided arguments to support chemotherapy-based salvage regimens and reasons why... [Read Article]

New agents challenge role of transplant in high-risk CLL



HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg
Preparing for HSCT
Credit: Chad McNeeley

The role of allogeneic hematopoietic stem cell transplant (HSCT) for patients with high-risk chronic lymphocytic leukemia (CLL) is changing in the age of targeted therapy. While allogeneic HSCT has been considered standard treatment for these patients, the question arises whether it will maintain its position in the era... [Read Article]

Panobinostat demonstrates ‘profound’ synergy with bortezomib



Richardson_Paul G_MD_L&M2014_240.jpg
Paul G. Richardson, MD

Calling the synergy with the proteasome inhibitor “profound,” Paul G. Richardson, MD, presented results on the combination of the pan deacetylase inhibitor panobinostat with bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM). The phase 3 PANORAMA 1 study confirmed data from the phase 1 and 2 trials, in which... [Read Article]

Chlorambucil’s role in untreated CLL debated



czuczman_myron_LM2014_240.jpg
Myron S. Czuczman, MD

With both the pro and con positions drawing on data from the phase 3 CLL11 trial, two speakers at the Lymphoma & Myeloma 2014 congress faced off on whether it’s necessary to use chlorambucil with obinutuzumab in untreated chronic lymphocytic leukemia (CLL). Myron S. Czuczman, MD, of Roswell Park Cancer Institute... [Read Article]